Biotech News

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

Corvus Pharmaceuticals (CRVS)Corvus Pharmaceuticals2026-06-25 13:46 ESTClinical readout

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following

Open original release

Related news

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

View all latest news

Corvus Pharmaceuticals

Corvus Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

CRVSZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

CRVSZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

CRVSBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

CRVSGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

CRVSMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 14.71 USD
Market cap: 1.32B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States